PCK1 is downstream of the mTOR pathway [9]; mTOR inhibition up-regulates PCK1 and shuttles glycolytic flux to the gluconeogenesis pathway, thereby inhibiting cellular proliferation in hepatocellular carcinoma and ccRCC [30]. Here, MTOR is linked to nonpapillary renal cell carcinoma.